121 related articles for article (PubMed ID: 12521127)
1. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer.
Morote J; Trilla E; Esquena S; Serrallach F; Abascal JM; Id H'Mammed Y; de Torres IM
Int J Biol Markers; 2002; 17(4):239-43. PubMed ID: 12521127
[TBL] [Abstract][Full Text] [Related]
2. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
3. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.
Erdem E; Atsü N; Akbal C; Bilen CY; Ergen A; Ozen H
Int Urol Nephrol; 2002; 34(4):519-23. PubMed ID: 14577496
[TBL] [Abstract][Full Text] [Related]
4. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
7. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
Pannek J; Rittenhouse HG; Chan DW; Epstein JI; Walsh PC; Partin AW
J Urol; 1998 Apr; 159(4):1238-42. PubMed ID: 9507844
[TBL] [Abstract][Full Text] [Related]
8. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
[TBL] [Abstract][Full Text] [Related]
9. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
10. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
12. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
Pannek J; Subong EN; Jones KA; Marschke PL; Epstein JI; Chan DW; Carter HB; Luderer AA; Partin AW
Urology; 1996 Dec; 48(6A Suppl):51-4. PubMed ID: 8973700
[TBL] [Abstract][Full Text] [Related]
13. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
14. Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSAPepe P; Panella P; Pietropaolo F; Pennisi M; Allegro R; Aragona F
Urol Int; 2006; 76(3):232-5. PubMed ID: 16601385
[TBL] [Abstract][Full Text] [Related]
15. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
16. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.
Bianco FJ; Wood DP; Cher ML; Powell IJ; Souza JW; Pontes JE
Clin Prostate Cancer; 2003 Mar; 1(4):242-7. PubMed ID: 15040883
[TBL] [Abstract][Full Text] [Related]
17. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
19. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
[TBL] [Abstract][Full Text] [Related]
20. Ability of sextant biopsies to predict radical prostatectomy stage.
Wills ML; Sauvageot J; Partin AW; Gurganus R; Epstein JI
Urology; 1998 May; 51(5):759-64. PubMed ID: 9610589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
